Haleos Labs Board Approves Q1FY27 Results, Reappoints Directors
Haleos Labs reported Q1FY27 results with standalone revenue at ₹67.83 crore and profit at ₹3.24 crore. Consolidated revenue was ₹72.94 crore with profit at ₹1.88 crore. The board approved re-appointment of two Independent Directors for a 5-year term and the 20th AGM on September 30, 2026.
The re-appointment of directors and the approval of financial results are standard corporate governance and reporting activities. The AGM date is also a routine event. The impact is medium as it confirms ongoing operations and leadership.
The announcement reports financial results and corporate actions like director re-appointments. While the results are presented, there isn't a significant positive or negative deviation indicated that would strongly sway sentiment.
Haleos Labs Limited announced the outcome of its 98th Board Meeting held on August 5, 2026. The Board approved the unaudited standalone and consolidated financial results for the quarter ended June 30, 2026. The company reported a standalone revenue from operations of ₹6,782.97 lakhs and a net profit of ₹323.78 lakhs for the quarter. Consolidated revenue from operations stood at ₹7,294.23 lakhs with a net profit of ₹188.31 lakhs.
Additionally, the Board approved the re-appointment of Dr. (Mr.) Mannam Malakondaiah and Dr. (Mr.) Srinivas Samavedam as Independent Directors for a second term of five years, effective November 13, 2026, subject to shareholder approval. The Board also approved the revision of managerial remuneration for Mr. TVVSN Murthy, Managing Director, also subject to shareholder approval.
The Board approved the Board's Report for the year ended March 31, 2026, and announced that the 20th Annual General Meeting will be held on Wednesday, September 30, 2026, through Video Conferencing ('VC') / Other Audio Visual Means ('OAVM'). The Board meeting commenced at 12:30 pm and concluded at 01:45 pm.
What to do with a filing like this
HALEOS LABS LIMITED filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by HALEOS LABS LIMITED. Read the original for the full detail.